Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Authors
Keywords
-
Journal
BMC CANCER
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2010-04-13
DOI
10.1186/1471-2407-10-136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer
- (2010) Monika L. Burness et al. CANCER JOURNAL
- KRAS Mutation Testing in Colorectal Cancer
- (2009) Thomas P. Plesec et al. ADVANCES IN ANATOMIC PATHOLOGY
- Management of Breast Cancer in the Genome Era
- (2009) Phuong Khanh H. Morrow et al. Annual Review of Medicine
- Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
- (2009) Helmout Modjtahedi et al. ANTI-CANCER DRUGS
- New Molecular Classifications of Breast Cancer
- (2009) M. Cianfrocca et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Assessment of K-rasmutation
- (2009) Yixing Jiang et al. CANCER
- Targeted therapy of metastatic breast cancer
- (2009) Alfonso Sánchez-Muñoz et al. Clinical & Translational Oncology
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
- (2009) Elena López-Knowles et al. INTERNATIONAL JOURNAL OF CANCER
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer
- (2008) Jeffrey Peppercorn et al. CANCER INVESTIGATION
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets
- (2008) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
- (2008) Fernanda Milanezi et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Basal-Like Breast Cancer: A Critical Review
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ras oncogenes: split personalities
- (2008) Antoine E. Karnoub et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and pathologic aspects of basal-like breast cancers
- (2008) Oluwole Fadare et al. Nature clinical practice. Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started